SG93776A1 - Peptides, fragments thereof, and preparation of compositions therefrom - Google Patents

Peptides, fragments thereof, and preparation of compositions therefrom

Info

Publication number
SG93776A1
SG93776A1 SG9603410A SG1996003410A SG93776A1 SG 93776 A1 SG93776 A1 SG 93776A1 SG 9603410 A SG9603410 A SG 9603410A SG 1996003410 A SG1996003410 A SG 1996003410A SG 93776 A1 SG93776 A1 SG 93776A1
Authority
SG
Singapore
Prior art keywords
peptide
high performance
liquid chromatography
performance liquid
phase high
Prior art date
Application number
SG9603410A
Other languages
English (en)
Inventor
James Smith Cooper Garth
Original Assignee
Amylin Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc
Publication of SG93776A1 publication Critical patent/SG93776A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Socks And Pantyhose (AREA)
SG9603410A 1987-08-26 1988-08-26 Peptides, fragments thereof, and preparation of compositions therefrom SG93776A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB878720115A GB8720115D0 (en) 1987-08-26 1987-08-26 Treatment of diabetes mellitus

Publications (1)

Publication Number Publication Date
SG93776A1 true SG93776A1 (en) 2003-01-21

Family

ID=10622830

Family Applications (1)

Application Number Title Priority Date Filing Date
SG9603410A SG93776A1 (en) 1987-08-26 1988-08-26 Peptides, fragments thereof, and preparation of compositions therefrom

Country Status (15)

Country Link
US (2) US5124314A (no)
EP (2) EP0787741A1 (no)
JP (1) JP2828250B2 (no)
AT (1) ATE155688T1 (no)
AU (1) AU634954B2 (no)
CA (1) CA1341060C (no)
DE (1) DE3855970T2 (no)
DK (1) DK473888A (no)
ES (1) ES2106721T3 (no)
FI (1) FI883936A (no)
GB (1) GB8720115D0 (no)
GR (1) GR3024705T3 (no)
HK (1) HK1000934A1 (no)
NO (1) NO883828L (no)
SG (1) SG93776A1 (no)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5298605A (en) * 1986-10-08 1994-03-29 Regents Of The University Of Minnesota Antibodies to islet amyloid polypeptide (IAPP) and subunits thereof
GB8709871D0 (en) * 1987-04-27 1987-06-03 Turner R C Peptides
US5266561A (en) * 1988-01-11 1993-11-30 Amylin Pharmaceuticals, Inc. Treatment of type 2 diabetes mellitus
GB8915712D0 (en) * 1989-07-08 1989-08-31 Macintyre Iain Medical treatment
US5405831A (en) * 1989-07-08 1995-04-11 Amylin Pharmaceuticals, Inc. Treatment of bone disorders
JP2533726Y2 (ja) * 1990-07-23 1997-04-23 船井電機株式会社 記録再生機器
US5260275A (en) * 1990-08-14 1993-11-09 Amylin Pharmaceuticals, Inc. Hypoglycemics
US5527771A (en) * 1991-01-10 1996-06-18 Amylin Pharmaceuticals, Inc. Methods and Compositions for treatment of diabetes mellitus, hypoglycemia & other conditions
US5321008A (en) * 1991-01-10 1994-06-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions
US5234906A (en) * 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
HU222249B1 (hu) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
WO1992015317A1 (en) * 1991-03-08 1992-09-17 Amylin Pharmaceuticals, Inc. Synthetic preparation of amylin and amylin analogues
EP0503827A1 (en) * 1991-03-15 1992-09-16 Pfizer Inc. Amylin and calcitonin gene-related peptide use and antagonists thereof
US5814600A (en) * 1991-05-24 1998-09-29 Amylin Pharmaceuticals Inc. Method and composition for treatment of insulin requiring mammals
AU669110B2 (en) * 1991-05-24 1996-05-30 Amylin Pharmaceuticals, Inc. Amylin and possibly insulin containing composition for the treatment of anorexia and related states
AU2169392A (en) * 1991-05-24 1992-12-30 Amylin Pharmaceuticals, Inc. Insulin and amylin containing composition for the treatment of insulin deficient mammals
US5580953A (en) * 1991-08-14 1996-12-03 Amylin Pharmaceuticals, Inc. Amylin antagonist peptides and uses therefor
US5763569A (en) * 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6031003A (en) * 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5858684A (en) * 1991-08-23 1999-01-12 The Brigham And Women's Hospital, Inc. Method of screening calcium receptor-active molecules
US6001884A (en) * 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5688938A (en) * 1991-08-23 1997-11-18 The Brigham & Women's Hospital, Inc. Calcium receptor-active molecules
US6011068A (en) * 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
ATE205854T1 (de) * 1991-11-19 2001-10-15 Amylin Pharmaceuticals Inc Peptide als amylin-agonisten und ihre verwendung
WO1993019774A1 (en) * 1992-04-03 1993-10-14 Amylin Pharmaceuticals, Inc. Amylin and possibly insulin containing composition for the treatment of anorexia and related states
DE69321473T2 (de) * 1992-08-06 1999-03-04 Pfizer Inc., New York, N.Y. Amylin muteine
US5376638A (en) * 1992-09-01 1994-12-27 Amylin Pharmaceuticals, Inc. Methods for treating renin-related disorders with amylin antagonists
US5545672A (en) * 1993-02-11 1996-08-13 The University Of Texas System Treatment of insulin resistance and type 2 diabetes mellitus with a thiol protease inhibitor
US5962314A (en) * 1993-02-23 1999-10-05 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
NZ250844A (en) * 1993-04-07 1996-03-26 Pfizer Treatment of non-insulin dependant diabetes with peptides; composition
JP3821839B2 (ja) * 1993-09-07 2006-09-13 アミリン・ファーマシューティカルズ，インコーポレイテッド 胃腸の運動性を調節する方法
KR950007873A (ko) * 1993-09-20 1995-04-15 후꾸하라 요시하루 생리 활성 물질 지속 방출형의 의약 제제
WO1996002269A1 (en) * 1994-07-13 1996-02-01 Auckland Uniservices Limited Therapeutic method and compounds of use therein
UA55374C2 (uk) 1994-10-21 2003-04-15 Нпс Фармасьютікалз, Інк Сполуки, що мають активність по відношенню до рецепторів кальцію
US6143718A (en) 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
US6110707A (en) * 1996-01-19 2000-08-29 Board Of Regents, The University Of Texas System Recombinant expression of proteins from secretory cell lines
EP0910578A2 (en) * 1996-01-19 1999-04-28 The Board Of Regents, The University Of Texas System Recombinant expression of proteins from secretory cell lines
ES2280460T3 (es) 1996-05-01 2007-09-16 Nps Pharmaceuticals, Inc. Compuestos activos frente a receptores de iones inorganicos.
US5677279A (en) * 1996-12-16 1997-10-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treating pain with amylin or agonists thereof
US7312196B2 (en) * 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US6410511B2 (en) 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US7101853B2 (en) 1997-05-06 2006-09-05 Amylin Pharmaceuticals, Inc. Method for treating or preventing gastritis using amylin or amylin agonists
US7910548B2 (en) * 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
DE19725619A1 (de) 1997-06-17 1998-12-24 Fraunhofer Ges Forschung Peptide als Agonisten und/oder Inhibitoren der Amyloidbildung und Zytotoxizität sowie der Verwendung bei Alzheimer'schen Krankheit, beim Typ II Diabetes mellitus und bei spongiformen Encephalopathien
US6821954B2 (en) 1997-09-18 2004-11-23 Auckland Uniservices Limited Compounds and uses thereof in treating bone disorders
AU5916298A (en) * 1998-01-09 1999-07-26 Amylin Pharmaceuticals, Inc. Amylin agonist pharmaceutical compositions containing insulin
US6936584B1 (en) 1998-02-13 2005-08-30 Amylin Pharmaceuticals, Inc. Mixed amylin activity compounds
US6087334A (en) * 1998-08-21 2000-07-11 Amylin Pharmaceuticals, Inc. Anti-diabetic peptides
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
WO2000078805A1 (en) * 1999-06-18 2000-12-28 Protemix Corporation Limited Peptide having preptin functionality
US20030166561A1 (en) * 1999-06-18 2003-09-04 Cooper Garth J. S. Peptide
EP1196189A2 (en) * 1999-06-25 2002-04-17 Medtronic MiniMed, Inc. Multiple agent diabetes therapy
US7022674B2 (en) * 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
CA2422911A1 (en) * 2000-09-19 2002-03-28 Paul Fraser New inhibitors of iapp fibril formation and uses thereof
WO2002067969A2 (en) 2001-02-21 2002-09-06 Medtronic Minimed, Inc. Stabilized insulin formulations
US6737401B2 (en) * 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
US20040038861A1 (en) * 2001-11-26 2004-02-26 Cooper Garth J. S. Methods and compositions for normalizing lipid levels in mammalian tissues
CA2471833A1 (en) * 2001-11-26 2003-06-05 Protemix Corporation Limited Methods of compositions for normalizing lipid levels in mammalian tissues
EP1474164B1 (en) * 2002-01-08 2008-10-29 Amylin Pharmaceuticals, Inc. Use of amylin, amylin analogs and amylin derivatives to treat dyslipidemia and triglyceridemia
US20040142393A1 (en) * 2002-08-01 2004-07-22 Cooper Garth James Smith Methods of use of compounds with preptin function
US8168233B2 (en) * 2002-10-18 2012-05-01 Amylin Pharmaceuticals, Inc. Treatment of pancreatitis with amylin
EP1631308B1 (en) 2003-05-30 2013-07-31 Amylin Pharmaceuticals, LLC Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
KR101196036B1 (ko) * 2003-07-01 2012-10-31 에센티스 에이비 영양실조 또는 높은 혈장 글루코스 상태를 치료하기 위한알파-케토글루타르산의 용도
CA2556226A1 (en) * 2004-02-11 2006-08-10 Amylin Pharmaceuticals, Inc. Amylin family peptides and methods for making and using them
JP2007522208A (ja) * 2004-02-12 2007-08-09 キャンピナ・ネダーランド・ホールディング・ビー．ブイ． チオールのホメオスタシスを改良するためのシステインリッチのペプチド
US7399744B2 (en) * 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
US20090069226A1 (en) * 2004-05-28 2009-03-12 Amylin Pharmaceuticals, Inc. Transmucosal delivery of peptides and proteins
EP2241327A1 (en) 2006-03-15 2010-10-20 Novo Nordisk A/S Mixtures of Amylin and Insulin
JP2010539042A (ja) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト ペプチドの治療剤としての使用
EP2036539A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Stable formulations of amylin and its analogues
KR20100057640A (ko) * 2007-09-11 2010-05-31 몬도바이오테크 래보래토리즈 아게 치료제로서의 인슐린 ｃ-펩티드 단독 또는 ｇｌｐ-1과의 배합물의 용도
JP5993147B2 (ja) 2009-03-12 2016-09-14 キーバイオサイエンス・アクチエンゲゼルシャフト 糖尿病およびメタボリックシンドロームの治療
ES2583259T3 (es) * 2009-12-01 2016-09-20 Novo Nordisk A/S Nuevas liasas alfa-amidantes de peptidil alfa-hidroxiglicina
WO2015003122A2 (en) 2013-07-03 2015-01-08 Alder Biopharmaceuticals, Inc. Regulation of glucose metabolism using anti-cgrp antibodies
WO2015196174A1 (en) 2014-06-20 2015-12-23 Greene Howard E Infusion delivery devices and methods
US10772556B2 (en) 2014-11-05 2020-09-15 Cláudio Afonso Ambrósio Method and system for monitoring and treating hypoglycemia
EP3562500B1 (fr) 2016-12-27 2023-07-19 Adocia Compositions sous forme de solution aqueuse injectable comprenant de l'amyline, un agoniste au récepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
FR3082426A1 (fr) 2018-06-14 2019-12-20 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant au moins de l'insuline humaine a21g et un suppresseur de glucagon a action prandiale
ES2969277T3 (es) 2017-07-27 2024-05-17 Adocia Composiciones en forma de una solución acuosa inyectable que comprenden al menos insulina humana A21G y un supresor de glucagón con acción prandial
FR3083089A1 (fr) 2018-06-29 2020-01-03 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
CA3084688A1 (fr) 2017-12-07 2019-06-13 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
SG11202005319PA (en) 2017-12-07 2020-07-29 Adocia Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid
FR3083085B1 (fr) 2018-06-29 2020-10-02 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
IL275146B1 (en) 2017-12-07 2024-09-01 Adocia Preparations in the form of an aqueous solution for injection that include amylin, an amylin receptor agonist or an amylin analog and copolyamino acid
FR3083086A1 (fr) 2018-06-29 2020-01-03 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
US20190275108A1 (en) 2017-12-07 2019-09-12 Adocia Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analogue and a co-polyamino acid
BR112020011486A2 (pt) 2017-12-07 2020-11-17 Adocia Solução injetável de ph 7 compreendendo pelo menos uma insulina basal comum pi de 5,8 a 8,5 e um copoliaminoácido contendo cargas de carboxilato e radicais hidrofóbicos
CN111565710A (zh) 2017-12-07 2020-08-21 阿道恰公司 包含胰淀素、胰淀素受体激动剂或胰淀素类似物以及共聚氨基酸的呈可注射水溶液形式的组合物
FR3084586B1 (fr) 2018-08-03 2020-11-06 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un compose amphiphile porteur de radicaux hydrophobes
EP3915571A1 (en) 2020-05-29 2021-12-01 Adocia Pharmaceutical composition in the form of an injectable aqueous solution including at least a rapid acting insulin analog and a glucagon suppressor with prandial action
EP3915572A1 (en) 2020-05-29 2021-12-01 Adocia Pharmaceutical composition in the form of an injectable aqueous solution including at least a rapid acting insulin analog and a glucagon suppressor with prandial action

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4687839A (en) * 1985-12-23 1987-08-18 Kempe Tomas G Calcitonin gene related peptide analogs with C-terminal D-amino acid substituents
EP0263802A1 (en) * 1986-10-08 1988-04-13 Per Westermark Kit of material containing a polypeptide of pancreatic islet amyloid and/or antibodies directed against said polypeptide, and use of said kit of material
EP0270376A2 (en) * 1986-12-04 1988-06-08 Asahi Kasei Kogyo Kabushiki Kaisha Calcitonin gene-related peptide derivatives

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2141430B (en) * 1983-06-15 1987-01-21 Kingdon Craig R Peptides, pharmaceutical compositions, genes, vectors, host organisms, processes for their production and diagnostic reagents
US4530838A (en) * 1983-07-08 1985-07-23 The Salk Institute For Biological Studies Synthetic calcitonin-gene-related peptides for lowering blood pressure or gastric acid secretion in mammals
GB8327346D0 (en) * 1983-10-12 1983-11-16 Morris H R Peptide
US4736023A (en) * 1983-12-23 1988-04-05 The Salk Institute For Biological Studies DNA encoding human CGRP
GB8407907D0 (en) * 1984-03-27 1984-05-02 Sandoz Ltd Organic compounds
DE3685885D1 (de) * 1985-01-16 1992-08-13 Ciba Geigy Ag Oligopeptide sowie zwischenprodukte und verfahren zu ihrer herstellung.
SE500044C2 (sv) * 1985-02-15 1994-03-28 Gambro Lundia Ab Peptidförening, antiserum framställt med användning av denna förening samt användning av föreningen
US4697002A (en) * 1985-12-23 1987-09-29 Kempe Tomas G Calcitonin gene related peptide analogs with amino acid subdstituents at the penultimate position 36
GB8709871D0 (en) 1987-04-27 1987-06-03 Turner R C Peptides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4687839A (en) * 1985-12-23 1987-08-18 Kempe Tomas G Calcitonin gene related peptide analogs with C-terminal D-amino acid substituents
EP0263802A1 (en) * 1986-10-08 1988-04-13 Per Westermark Kit of material containing a polypeptide of pancreatic islet amyloid and/or antibodies directed against said polypeptide, and use of said kit of material
EP0270376A2 (en) * 1986-12-04 1988-06-08 Asahi Kasei Kogyo Kabushiki Kaisha Calcitonin gene-related peptide derivatives

Also Published As

Publication number Publication date
CA1341060C (en) 2000-07-25
AU634954B2 (en) 1993-03-11
DK473888A (da) 1989-04-05
NO883828D0 (no) 1988-08-26
EP0787741A1 (en) 1997-08-06
EP0309100B1 (en) 1997-07-23
GB8720115D0 (en) 1987-09-30
FI883936A (fi) 1989-02-27
DE3855970D1 (de) 1997-09-04
EP0309100A2 (en) 1989-03-29
JPH0196137A (ja) 1989-04-14
FI883936A0 (fi) 1988-08-25
JP2828250B2 (ja) 1998-11-25
DE3855970T2 (de) 1998-01-29
ATE155688T1 (de) 1997-08-15
HK1000934A1 (en) 1998-05-08
ES2106721T3 (es) 1997-11-16
US5641744A (en) 1997-06-24
DK473888D0 (da) 1988-08-25
GR3024705T3 (en) 1997-12-31
NO883828L (no) 1989-02-27
US5124314A (en) 1992-06-23
EP0309100A3 (en) 1991-04-03
AU2157588A (en) 1989-07-20

Similar Documents

Publication Publication Date Title
SG93776A1 (en) Peptides, fragments thereof, and preparation of compositions therefrom
Shimizu et al. Proteolytic enzyme in porcine immature enamel
Chance Amino acid sequences of proinsulins and intermediates
HU902697D0 (en) Process for the enzymatic removal of the n-terminal sequence of proteins
DE10075019I2 (de) Neue Proteine mit TNF-Hemmender Wirkung und ihre Herstellung.
KR890003802A (ko) 재조합 dna 기술에 의해 제조된 소의 췌장 트립신 억제제, 그 제조 방법, 발현 벡터 및 재조합 숙주 및 그의 제약적 용도
HUT63457A (en) Process for producing triarginine insulins
JPH06500311A (ja) ヒスチジン置換されたヒト成長ホルモン放出因子類縁体
DE69123106D1 (de) Polypeptid, das zur Interaktion mit Thrombin fähig ist
CA2208274A1 (en) Peptide p277 analogs, and pharmaceutical compositions comprising them for treatment or diagnosis of diabetes
AU2308992A (en) Cysteine depleted il-6 muteins
SAITOH et al. Further Fractionation of Basic Proline-Rich Peptides from Human Parotid Saliva and Complete Amino Acid Sequence of Basic Prolme-Rich Peptide PH
EP0249477A3 (en) Functional recombinant analog polypeptides devoid of hydrophobic amino acids
Butler et al. Homologous regions of collagen α1 (I) and α1 (II) chains: Apparent clustering of variable and invariant amino acid residues
Fenger α-Melanocyte-stimulating-hormone precursors in the pig pituitary
Ohta et al. The amino acid sequence of toxin D isolated from the venom of Indian cobra (Naja naja)
Lopez-Trascasa et al. Isolation and characterization of a biologically active C2 derived oligopeptide
Saito et al. Sialoglycopeptides Isolated from Bovine. Aorta
Maita et al. The amino acid sequences of the two main components of adult hemoglobin from orangutan (Pongo pygmaeus)
Champagne et al. The Core Histones from the Slime Mold Physarum polycephalum: Isolation and Characterization
WADE et al. DIABETOGENIC ACTION OF HUMAN GROWTH HORMONE Synthesis and Activity of C‐terminal Fragments
Sanger Les Prix Nobel en 1958
Monahan et al. Studies of the interaction of C8 and C9 within the membrane-bound cytolytic complex of complement
CA2083286A1 (en) Recombinant fibrinogenases, preparation and use thereof
EP0290029A3 (en) (19-alanine) calcitonin